Gene One Life Science

Gene One Life Science EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Gene One Life Science (011000.KS) as of Oct 26, 2026 is -10.29. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -8.54 — a change of 20.48% (lower).

EV/FCF

-10.29

YoY

20.48%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Gene One Life Science is 2025 -10.29 . EV/FCF (Enterprise Value to Free Cash Flow) of Gene One Life Science was 2024 -8.54 . It decreases by 20.48% lower compared to the previous year.

The Gene One Life Science EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-11.94 KRW
Jan 1, 2019
-32.15 KRW
Jan 1, 2020
-2.10 KRW
Jan 1, 2021
-0.59 KRW
Jan 1, 2022
-1.65 KRW
Jan 1, 2023
-5.39 KRW
Jan 1, 2024
-8.54 KRW
Jan 1, 2025
-10.29 KRW
The Gene One Life Science EV/FCF history
YEAREV/FCFYoY
-10.29+20.48%
-8.54+58.42%
-5.39+227.04%
-1.65+179.33%
-0.59-71.90%
-2.10-93.47%
-32.15+169.27%
-11.94-55.47%
-26.81+213.13%
-8.56-90.44%
-89.54+259.09%
-24.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gene One Life Science Stock analysis

What does Gene One Life Science do? GeneOne Life Science, Inc. generates revenue through its biomedical contract manufacturing organization (CMO) services, producing DNA vaccines for disease prevention and treatment. The company also sells wicks under the brand INTERON for use in dress shirts, suits, and caps, and provides biopharmaceutical services including research, development, and manufacturing of plasmid DNA and DNA vaccines. Its leasing business involves nonresidential buildings. The primary buyers for the biomedical CMO services are likely pharmaceutical companies seeking contract manufacturing for DNA vaccines. INTERON wicks are purchased by apparel manufacturers producing dress shirts, suits, and caps. The leasing segment targets commercial property tenants requiring nonresidential space. The company serves the biomedical, textile, and real estate sectors through these distinct business segments. Gene One Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gene One Life Science stock

EV/FCF (Enterprise Value to Free Cash Flow) of Gene One Life Science is -10.29 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Gene One Life Science changed from -8.54 to -10.29, representing a 20.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Gene One Life Science since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Gene One Life Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Gene One Life Science

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Gene One Life Science